New insights into ivermectin’s potential role in cancer treatment emerged from ongoing research and discussions on X. A significant update involves a phase I/II clinical trial at Cedars-Sinai Medical Center, led by Yuan Yuan et al., evaluating ivermectin combined with balstilimab for metastatic triple-negative breast cancer. The trial, reported at the 2025 ASCO meeting, includes 45 patients, with preliminary data showing no significant reduction in tumor size after 12 weeks, though 8 patients exhibited stable disease. Additionally, a review by Yuwen et al., published in 2025, analyzed 2,273 studies to assess ivermectin’s preclinical antitumor activity, identifying mechanisms like oxidative stress induction and mitochondrial disruption across 15 cancer types, including bladder, lung, and glioma. The review noted ivermectin’s safety in low doses but highlighted the need for further human trials. Separately, a study by Morinaga et al. in 2025 demonstrated that ivermectin, combined with recombinant methioninase, eradicated 90% of MiaPaCa-2 pancreatic cancer cells in vitro, suggesting potential synergy with other therapies. Posts on X also reflect growing interest, with users citing case reports of tumor shrinkage, though no large-scale randomized controlled trials confirm these outcomes. The research continues to explore ivermectin’s role, with ongoing trials expected to provide more data by late 2025.
www.34news.online
www.34news.online
